AXSM Axsome Therapeutics Inc

🔔Mid Day Trading Update🔔 📅Monday 28/11/2022📅 🟢Bullish Activity🟢 $AXSM Gapping up to a 52 week high this morning after the biopharmaceutical company announced that its experimental Alzheimer’s drug AXS-05 met the primary and key secondary endpoints in the Assessing Clinical Outcomes in Alzheimer’s Disease Agitation Phase 3 trial. AXS-05 substantially and statistically significantly delayed the time to relapse a 3.6-fold lower risk and prevented relapse of agitation in patients with Alzheimer’s disease as compared to the placebo. The December 16th 100.00 call being the highest volume contract. $BUD Also to the upside after JP Morgan double upgraded the alcoholic beverage maker to Overweight from Underweight and lifted their price target on the stock to $70.00 from $45.00. Analyst Jared Dinges said that he now sees the potential for earnings outperformance and believes the rapid deleveraging of the company’s balance sheet will provide optionality. The December 16th 60.00 call be